Mounjaro(Tirzepatide) is a drug for weight loss and maintenance that contains the active substance tirzepatide. Tirzepatide is a long-acting dual GIP and GLP-1 receptor agonist. Both receptors are found in pancreatic alpha and beta endocrine cells, heart, blood vessels, immune cells (leukocytes), intestines and kidneys. GIP receptors are also found in adipocytes.
In addition, both GIP and GLP-1 receptors are expressed in brain regions that are important for appetite regulation. Tirzepatide is highly selective for human GIP and GLP-1 receptors. Tirzepatide has a high affinity for both GIP and GLP-1 receptors. The activity of tirzepatide at GIP receptors is similar to that of the natural GIP hormone. The activity of tirzepatide at GLP-1 receptors is lower than that of the natural GLP-1 hormone.
Mounjaro(Tirzepatide) works by acting on receptors in the brain that control appetite, making you feel fuller, less hungry, and less likely to crave food. This will help you eat less and lose weight.
Mounjaro should be used with a reduced-calorie meal plan and increased physical activity.
Inclusion Criteria
Mounjaro(Tirzepatide) is indicated for weight management, including weight loss and maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of:
≥ 30 kg/m2 (obese), or
≥ 27 kg/m2 to <30 kg/m2 (overweight) with at least one weight-related comorbidity such as dysglycemia (prediabetes or type 2 diabetes), hypertension, dyslipidemia, or obstructive sleep apnea Consent to treatment and adherence to an adequate dietary intake
Age 18-75 years
If a patient fails to lose at least 5% of their initial body weight after 6 months of treatment, a decision needs to be made whether to continue treatment, taking into account the benefit/risk profile of the individual patient.
Dosing schedule
The starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, the dose should be increased to 5 mg once weekly. If needed, the dose may be increased by 2.5 mg for at least 4 weeks on top of the current dose.
The recommended maintenance doses are 5, 10, and 15 mg.
The maximum dose is 15 mg once weekly.
Dosing method
Mounjaro(Tirzepatide) may be administered once weekly at any time of the day, with or without food.
It should be injected subcutaneously in the abdomen, thigh, or upper arm. The injection site may be changed. It should not be injected intravenously or intramuscularly.
If needed, the weekly dosing day may be changed as long as the time between doses is at least 3 days (>72 hours). Once a new dosing day is selected, dosing should continue once weekly.
Patients should be advised to read the instructions for use in the package insert carefully before taking the medicine.
Post time: Feb-15-2025